GLP-1 myths on TikTok: what @sirmixaflock probably got right and wrong

What did @sirmixaflock actually say?

The creator responded to a viewer named Becca who is on 2.4mg of what they called "pomegluetide" (almost certainly semaglutide), eating 1,250 calories a day, doing bootcamp and Pilates, and not eating much protein. The creator offered three possible reasons for her plateau: her medication dose or type may need revisiting, her calorie deficit may not be as large as she thinks, and she may not be working as hard in her workouts as she believes. They also explained the thermic effect of food, specifically that protein burns roughly 30% of its calories during digestion compared to about 10% for carbs and 3% for fat.

To their credit, they repeatedly told Becca to talk to her doctor about medication changes and suggested hiring a coach rather than prescribing anything themselves. That restraint matters on a platform where half the GLP-1 content is essentially unlicensed telehealth.

Does the science back this up?

Mostly, yes, with a few numbers that need tightening. The core claims about thermic effect of food, caloric deficit math, and protein's role in weight loss are grounded in real evidence. The thermic effect of protein is the most well-documented of the three, and the creator's ballpark figures are in the right range, even if they hedged appropriately.

On the calorie deficit claim, the oft-cited "3,500 calories per pound of fat" rule, which implies 500 calories/day deficit yields about 1 pound/week, is a reasonable clinical approximation but has been challenged. Thomas et al. (2014, Lancet Diabetes and Endocrinology) showed that the relationship between deficit and weight loss is non-linear over time, partly because metabolic adaptation kicks in. So the creator's "500 calories per day, half a pound to a pound per week" estimate is a useful starting point, not a guarantee.

On GLP-1 plateau management, the suggestion to discuss a dose increase or a switch to tirzepatide is clinically reasonable. Davies et al. (2021, The Lancet) and the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) both support tirzepatide producing greater weight loss than semaglutide at comparable doses, though head-to-head comparisons still have limitations.

What did they get wrong (or right)?

The drug name is wrong. "Pomegluetide" is not a real medication name. The creator almost certainly means semaglutide, the active ingredient in Ozempic and Wegovy. At 2.4mg, this is the FDA-approved maintenance dose of Wegovy. Getting the name that wrong on a health-focused platform is sloppy and worth correcting.

The thermic effect of food numbers are close but slightly off. The research range for protein TEF is typically 20-30% (Westerterp, 2004, Nutrition and Metabolism), so saying "up to 30%" is defensible. Carbohydrates are generally 5-10%, so "up to 10%" is fair. Fat is typically 0-3%, so "only like 3%" is roughly accurate. The creator flagged their own uncertainty here, which is honest.

What they got right: recommending Becca examine her actual BMR, pushing protein intake, suggesting a professional coach audit her workouts, and repeatedly deferring medical decisions to a physician. These are all appropriate and evidence-aligned recommendations. The workout intensity point is also well-taken. Research on perceived exertion consistently shows people overestimate effort in self-directed exercise (Lagally et al., 2002, Journal of Strength and Conditioning Research).

What should you actually know?

If you are on semaglutide at 2.4mg and hitting a plateau, there are a few things worth understanding before your next doctor visit. GLP-1 receptor agonists work partly through appetite suppression, and that suppression can diminish over time at a fixed dose. That is a pharmacological reality, not a personal failure.

Calorie restriction below roughly 1,000-1,200 calories, especially without adequate protein, can accelerate lean muscle loss. This is particularly relevant for people doing resistance training, because muscle tissue is metabolically active and losing it slows your resting metabolic rate. Cava et al. (2017, Nutrients) found that high-protein diets during caloric restriction significantly preserved lean mass compared to standard-protein diets.

The creator's suggestion to "just Google your BMR" is directionally fine but incomplete. BMR calculators do not account for metabolic adaptation, which can reduce your actual energy expenditure by 10-15% after sustained caloric restriction (Leibel et al., 1995, NEJM). A registered dietitian with GLP-1 experience will give you a far more accurate picture than any calculator.

And one more thing: the creator compared their own 1,250-calorie intake as a 196-pound, 6'1" male to Becca's situation to make a point about relative deficit size. That comparison is not entirely useful without knowing Becca's height, weight, and activity level. Use it as a rough illustration, not a framework for your own intake.